Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know

Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know

Abstract Immune checkpoint inhibitors (ICIs) have made a breakthrough in the treatment of different types of tumors, leading to improvement in survival, even in patients with advanced cancers. Despite the good clinical results, a certain percentage of patients do not respond to this kind of immunoth...

Full description

Bibliographic Details
Main Authors: Simone Camelliti, Valentino Le Noci, Francesca Bianchi, Claudia Moscheni, Francesca Arnaboldi, Nicoletta Gagliano, Andrea Balsari, Marina Chiara Garassino, Elda Tagliabue, Lucia Sfondrini, Michele Sommariva
Format: Article
Language:English
Published: BMC 2020-11-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Hyperprogressive disease
Immune checkpoint inhibitors
Immunotherapy
Immune-mediated mechanisms
Online Access:http://link.springer.com/article/10.1186/s13046-020-01721-9

Internet

http://link.springer.com/article/10.1186/s13046-020-01721-9

Similar Items